Acurx Pharmaceuticals Inc. Common Stock (ACXP)
Stock · NASDAQ · Health Care
$1.1as of 10/16/2026
Price chart
Active signals
ACXP Signal Track Record
How signals performed across all stocks →What ACXP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band BreakdownActive now | 26 | +3.2% | 58% | September 29, 2026 |
| Bollinger Band Breakout | 18 | -11.5% | 33% | August 17, 2026 |
| Volume Spike | 16 | -7.1% | 31% | September 16, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -5.0% | 25% | March 5, 2024 |
| Any 20-session window (baseline) | -8.2% | 31% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parentera…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 4
- Website
- www.acurxpharma.com/
Fundamentals
- 1-day range
- $1.15$1.22
- Market cap
- $6.27M
- P/E (trailing)
- —
- P/E (forward)
- -0.67
- EPS (trailing)
- $-3.10
- Dividend yield
- —
- Beta
- -2.14
- Avg. volume
- 121.4K
Forecasts
3 analyst ratings
Acurx Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ACXPAcurx Pharmaceuticals Inc. Common Stock$1.1▼ 5.98%Market cap $6.27MP/E —$1.15$7.87
- ENVBEnveric Biosciences Inc. Common Stock$1.38▼ 0.72%Market cap $6.28MP/E —$1.17$13.25
- HCWBHCW Biologics Inc. Common Stock$1.24▲ 0.81%Market cap $6.19MP/E —$1.14$27.3
- APVOAptevo Therapeutics Inc. Common Stock$1.62▼ 4.71%Market cap $6.18MP/E 0.00$1.37$30.06
- GELSGelteq Limited Ordinary Shares$0.446▲ 3.48%Market cap $6.15MP/E —$0.387$2.01
- PULMPulmatrix Inc. Common Stock$1.36▼ 3.55%Market cap $6.06MP/E —$1.16$5.24
- XBIOXenetic Biosciences Inc. Common Stock$1.99▼ 1.00%Market cap $6.53MP/E —$1.87$5.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ACXP Acurx Pharmaceuticals Inc. Common Stock | $6.27M | — | $1.1 | ▼ 5.98% | $1.15$7.87 |
| ENVB Enveric Biosciences Inc. Common Stock | $6.28M | — | $1.38 | ▼ 0.72% | $1.17$13.25 |
| HCWB HCW Biologics Inc. Common Stock | $6.19M | — | $1.24 | ▲ 0.81% | $1.14$27.3 |
| APVO Aptevo Therapeutics Inc. Common Stock | $6.18M | 0.00 | $1.62 | ▼ 4.71% | $1.37$30.06 |
| GELS Gelteq Limited Ordinary Shares | $6.15M | — | $0.446 | ▲ 3.48% | $0.387$2.01 |
| PULM Pulmatrix Inc. Common Stock | $6.06M | — | $1.36 | ▼ 3.55% | $1.16$5.24 |
| XBIO Xenetic Biosciences Inc. Common Stock | $6.53M | — | $1.99 | ▼ 1.00% | $1.87$5.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price Targetbenzinga · 9/29/2026
- Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile InfectionYahoo · 9/29/2026
- HC Wainwright & Co. Reiterates Buy on Acurx Pharmaceuticals, Maintains $31 Price TargetBenzinga · 9/29/2026
- Acurx Pharmaceuticals Says First Patient Enrolled In New PATHFINDER Clinical Trial In Patients With Multiply Recurrent C. Difficile InfectionBenzinga · 9/29/2026
- New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace GlobalYahoo · 9/19/2026
- Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference CallBenzinga · 9/18/2026
- Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-CulturesYahoo · 9/14/2026
Insider Activity
Insider Actions →- Thomas L. Harrison · April 20, 2026 · Grant2.1K
- Robert J. Deluccia · April 20, 2026 · Grant37.1K
- Carl Sailer · April 20, 2026 · Grant2.1K
- James J. Donohue · April 20, 2026 · Grant2.1K
- Shawah Robert G. · April 20, 2026 · Grant25.9K
- Jack H. Dean · April 20, 2026 · Grant2.1K
- Joseph C. Scodari · April 20, 2026 · Grant2.1K
- David P. Luci · April 20, 2026 · Grant37.1K
Institutional Ownership
March 31, 2026
- Total shares held
- 167.0K
- Total value held
- $545.1K
- Institutional holders
- 21
- Unknown54.6K
- Unknown31.1K
- Unknown24.8K
- Unknown20.0K
- Unknown13.8K
- Unknown6.5K
- Unknown6.3K
- Unknown2.3K
- Unknown1.6K
- Unknown1.5K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial
Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.
Acurx Enrolls First Patient in PATHFINDER C. Diff Trial. Acurx Pharmaceuticals announced that the first patient has been enrolled in its PATHFINDER clinical trial for ibezapolstat, a treatment for multiply-recurrent C. difficile infection. This milestone marks a key step in the drug's development process. The company's stock is currently trading near its 52-week low, while analysts maintain a wide range of price targets.